Fig 1.
Structures of selected marketed antitubercular drugs containing pyridine and tetrahydropyran scaffolds.
Fig 2.
Fluorinated chalcones, pyridine and pyran derivatives with significant antitubercular activity.
Fig 3.
Scheme 1, Synthesis of fluorinated chalcones (1–20) and their 2-amino-pyridine-3-carbonitrile (21–40) and 2-amino-4H-pyran-3-carbonitrile (41–60) derivatives.
Fig 4.
Summary of the antitubercular activities of fluorinated chalcones (1–20), 2-amino-pyridine-3-carbonitrile (21–40) and 2-amino-4H-pyran-3-carbonitrile (41–60) derivatives.
Fig 5.
Structure activity relationships of fluorinated chalcones (1–20), 2-amino-pyridine-3-carbonitrile (21–40) and 2-amino-4H-pyran-3-carbonitrile (41–60) derivatives.
Fig 6.
2D and 3D interactions of 40 with PZA active site of 1G3U, which shown hydrogen bond and other interactions.